KCM
PRLD icon

Kynam Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Kynam Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.45M Buy
1,592,551
+803,684
+102% +$2.11M 0.34% 34
2025
Q4 		$2.29M Buy
+788,867
New +$1.33M 0.15% 37

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kynam Capital Management's PRLD Position: Q1 2026 in Review

Kynam Capital Management increased its Prelude Therapeutics (PRLD) stake by 102% in Q1 2026, buying an estimated $2.11M and bringing the position to 1,592,551 shares worth $5.45M. The position accounts for 0.34% of the portfolio, ranked #34.

Kynam Capital Management first reported a position in PRLD in Q4 2025 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Kynam Capital Management held 1,592,551 shares of Prelude Therapeutics worth $5.45M as of Q1 2026.
  • Kynam Capital Management bought 803,684 Prelude Therapeutics shares in Q1 2026, an estimated $2.11M.
  • Prelude Therapeutics made up 0.34% of Kynam Capital Management's portfolio in Q1 2026, its #34 holding.
  • Kynam Capital Management first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.